• SCYNEXIS posted Q2 net income of USD 7.4 million, swinging from a net loss, as warrant liability gains rose to USD 14.2 million.
• Operating loss narrowed 18.7% to USD 7.78 million; revenue fell 82.8% to USD 235,000.
• R&D expense dropped 45.5% to USD 3.89 million, while SG&A increased 8.9% to USD 4.12 million.
• Cash, cash equivalents and investments totaled USD 71.1 million at June 30, up from USD 56.3 million at Dec. 31.
• Pipeline focus shifted to SCY-770 for ADPKD, with a Phase 1 confirmatory study due in Q3 2026 and Phase 2 start expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-26-000027), on August 10, 2026, and is solely responsible for the information contained therein.